May 7, 2013
InterWest Partners, Sutter Hill Ventures and Astellas Venture Management
Invest $15 Million into Tacurion to Advance Compound
TOKYO, JAPAN and BRIDGEWATER, N.J., May 7, 2013 – Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) and Drais Pharmaceuticals, Inc. (“Drais”) today...
CAMBRIDGE, Mass. and TOKYO, Japan, May 2, 2013 - AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today reported that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted that the application for investigational agent tivozanib did not demonstrate a favorable benefit-to-risk evaluation for the treatment of advanced renal cell carcinoma (RCC) in an adequate and well-controlled trial (13 to 1, 0 abstentions)....
- Retrospective analysis of linagliptin data in sub-populations with type 2 diabetes presented at AACE 22nd Annual Scientific & Clinical Congress
Ahead of the "Move for Health Day" (10 May) and the "European Stroke Day" (14 May), the Stroke Alliance for Europe (SAFE) and Bayer HealthCare jointly raise their voices that society cannot afford not to prevent cardiovascular diseases. As the worldwide leading cause of death, the consequences of cardiovascular disease are immense. Cardiovascular disease has no geographic...
May 6, 2013
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced that results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, the peer-reviewed journal of the American Heart Association. Results from this subanalysis showed that the reductions in stroke or systemic embolism, number of...- Lilly Announces CEO Dr. John Lechleiter to Undergo Scheduled Surgery
- Today, the U.S. Food and Drug Administration issued a proposed order that, if finalized, would reclassify sunlamp products and require labeling to include a recommendation designed to warn young people not to use these devices.
- The U.S. Food and Drug Administration is alerting health care providers and patients that medications including and related to valproate sodium can cause decreased IQ scores in children whose mothers took the medication during pregnancy. Therefore, these drugs are being contraindicated for (should never be used by) pregnant women for the prevention of migraine headaches. Valproate products include valproate sodium (Depacon), divalproex sodium (Depakote, Depakote CP, and Depakote ER), valproic...